Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.




There is on-going development of generic EU CTD Dossier of  Donepezil, tablets, 5-10 mg.

Dossier should be available in December 2006.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Donepezil (also misspelled donezepil), marketed under the trade name Aricept by its developer Eisai and partner Pfizer, is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. Its binding to the acetylcholinesterase can be seen at Proteopedia 1eve. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks.

More details at: http://www.rxlist.com/aricept-drug.htm

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 30

Advertiser details

Contact Advertiser

Add comment


Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

Lokking for EU CTD Dossiers for traditional...
Member of  Farmavita.Net from EU is looking to...
We are looking to acquire Azathioprine tablet...
I am looking for a good quality dossier with...
We offer for outlicensing European e-CTD...
Novel herbal based throat pastilles with...
We are looking for EU-CTD dossier...